If you need to contact our communication department, please do it by contacting:

  • Miguel Martínez-Cava
  • Olaya Fernández Díez
  • Pharma Mar Communication Dept.
  • Phone: +34 91 846 6000

Press releases

No posts found.

Zeltia subsidiary Sylentis commences Phase I trials with its new compound SYL1001 to treat eye pain associated with dry eye syndrome

SYL1001 is a new compound arising from Sylentis’s research in ophthalmological disorders  It is indicated for treating eye discomfort associated with dry eye syndrome  SYL1001 is a form of interference RNA (RNAi)  SYL1001 inhibits the capsaicin receptor TrpV1, which is expressed on the surface of the eye

Sylentis receives authorisation to commence Phase IIb clinical trial with bamosiran (SYL040012) for treating ocular hypertension associated with glaucoma

The main endpoint of the trial is to establish the most effective dose of bamosiran for reducing intraocular pressure after 28 days’ treatment.  The Phase IIb trial with bamosiran will be conducted at 21 centres in Spain, Germany, Estonia and the United States, enrolling 180 patients. Madrid, 17 July 2014: Grupo

Zeltia announces that subsidiary Sylentis has attained the primary endpoint of the Phase IIa clinical trial with its compound SYL040012.

SYL040012 is a novel compound arising from Sylentis’s research in ophthalmological disorders. It is indicated for treating ocular hypertension associated with glaucoma. SYL040012 is a chemical entity under the heading of interference RNA (RNAi). Sylentis is one of only five companies in the world with RNAi-based products undergoing clinical trials.

Sylentis (PharmaMar Group) at ARVO 2019 with results from two ophthalmic drugs: tivanisirán and SYL1801

The company will present results of the HELIX clinical trial with tivanisirán for the treatment of Dry Eye Syndrome, in which an improvement in central corneal damage and results in patients with Sjögren’s Syndrome are demonstrated. Sylentis will also present data from the development of SYL1801 for the treatment and

Sylentis announces new preclinical and clinical data for its SYL1001 molecule during ARVO 2017

SYL1001 is a compound under investigation for the treatment of dry eye disease. It is a product based on the novel technology RNA interference (RNAi), developed for the treatment of signs and symptoms of this illness. At the Annual Congress of the Association for Research in Vision and Ophthalmology 2017,

Sylentis, a pioneer in RNAi technology, obtains authorisation as research drug manufacturing laboratory

Sylentis, a biopharmaceutical company in Grupo Zeltia (MC:ZEL) which is a pioneer in the research and development of new drugs based on gene silencing (interference RNA: RNAi) and one of the four companies in the world with RNAi-based products undergoing clinical trials, has been authorised as a pharmaceutical laboratory to

Sylentis announces top-line results from Phase II study SYLTAG for RNAi drug bamosiran (SYL040012) in Glaucoma

All bamosiran doses similarly reduced the intraocular pressure (IOP). In patients with a baseline IOP greater than or equal to 25 mm Hg, 1.125% bamosiran showed more efficacy  The trial did not meet the secondary objective of demonstrating non-inferiority compared to timolol in the total patient population; however, bamosiran at

Sylentis announces results of Phase 3 HELIX trial with tivanisiran for the treatment of Dry Eye Disease

The HELIX trial has shown improvement (p=0.035) in the reduction of central corneal staining Data will be presented to the FDA and other regulatory authorities during the second quarter of 2019 to define the regulatory strategy The results of the HELIX trial will be presented at the Annual Congress of

Sylentis presents new data on a new eye drop siRNA for the treatment of retinal diseases avoiding intraocular injections

This new investigational treatment, based on RNA interference, reaches the retina when administered in eye drops. This feature is expected to positively affect patients’ quality of life by eluding the use of current standard treatments administered by intraocular injections.   Madrid, 25 September 2017. Sylentis presents, for the first time,

Sylentis, PharmaMar Group, announces the end of patient recruitment for its HELIX trial

Sylentis has reached the target of recruiting patients for its Phase III trial “HELIX” for the treatment of the signs and symptoms of dry eye disease. We estimate that the results of the trial will be available in the first four months of 2019.   Madrid, October 19th, 2018.- Sylentis,
error: Content is protected !!